To add to that, we have a major problem with tuberculosis drug development. We are quite simply running out of viable options, and this is a global problem. The Canadian tuberculosis standards reflect global treatment options that are available to everyone, and the options are quite limited. This is a disease for which there is a growing resistance to the drugs that we have available.
In the last 40-plus years, two drugs have entered the market for a disease for which there are 10 million new cases and close to two million deaths per year—two drugs since 1971. Neither is registered in Canada.
In fact, registration of bedaquiline, which Rachel talked about, is also a global problem. We issued an open letter on September 17 of this year calling for broader registration of bedaquiline, because it is not registered in 18 high-burden countries around the world despite the fact that the development of the drug was a collaborative effort that involved health charities, pharmaceutical companies, public funds and so on.